Uttar Pradesh COVID-19 Case Decline Continues as Authorities Lift Restrictions in 72 or 75 State Districts: What Was in those Medicine Kits?

Uttar Pradesh COVID-19 Case Decline Continues as Authorities Lift Restrictions in 72 or 75 State Districts What Was in those Medicine Kits

As TrialSite chronicled, the COVID-19 case count takes a dramatic turnaround, from an incredibly scary and dangerous spike in cases that was part of the intense Indian second wave of the pandemic to just less than two months later. near-record low reports of cases to the point where authorities have lifted COVID-19 restrictions in 72 of the 75 districts across the state. What’s behind this turnaround is, of course, controversial in that TrialSite strongly suggests that a population-wide public health scheme, including ivermectin-based home medicine kit, isn’t getting recognized by public health authorities and non-governmental organizations (NGOs). such as World Health Organization (WHO), due to information suppression associated with bias and vested economic interests. Now Uttar Pradesh has lifted COVID-19 lockdown restrictions in 72 of 75 districts in the nation’s most populated state, revealing what can only be described as an incredible turn of events. Even showcased by WHO recently, the worldwide NGO noted that aggressive population-wide health schemes, including home testing and ‘medicine kits,’ made this turnaround possible given the virulent nature of the Indian variant of the coronavirus. Why didn’t the WHO share with the world what was in those medicine kits? What do they have to hide?

The second dangerous wave started in India in late March/early April and in Uttar Pradesh, India’s most populated state, by April 1 an estimated 2,589 new daily cases were reported as revealed by data derived from Johns Hopkins University. In an unprecedented spike, those daily cases rapidly ascended to 37,944 cases by April 24. Around the same time, India included ivermectin on its national COVID-19 treatment guidelines but it’s important to note that TrialSite has reported for over a year that Uttar Pradesh had already authorized the use of the drug. 

By May 8, TrialSite chronicled that due to the national authorization of ivermectin for COVID-19, companies such as Bajaj Healthcare (BHL) were authorized to sell a commercialized version of Ivermectin called Ivejaj. We shared that at least in India Ivermectin was authorized with over 50 clinical trials and observational studies revealing positive results not to mention some real-world and anecdotal data around the country as the drug was already in use in various states or in specific municipalities and hospitals targeting the virus.

By May 12, TrialSite reported that the use of Ivermectin as a Prophylactic and therapeutic course of treatment, we suspected but could not absolutely prove, had not only lowered transmission and infection rates but also served to reduce the death rate as well.

Again on May 14, TrialSite shared that the cases continued to drop in this state with approaching 240 million people making it more populous than the nation of Brazil.  Cases were down from 33,531 on April 26 to just 18,023 on May 12, again based on Johns Hopkins University data.

By May 30 in an “Unprecedented Pandemic Turnaround in Uttar Pradesh with Dramatic Decline in Cases,” TrialSite shared that conditions were improving so much that health authorities in Uttar Pradesh were planning an easing up of COVID-19-based restrictions, at least in zones of the state where the COVID-19 infection numbers were below 600 cases.

What is the World Health Organization’s (WHO) Position?

TrialSite chronicled the position of WHO on this striking turnaround of cases. What was responsible for the turnaround according to the WHO? In fact, WHO declared in “Going the Last Mile to Stop COVID-19”  that Uttar Pradesh could attribute the success to local public health actions including the provisioning of home “medicine kits” proactively given out to the population. But TrialSite reminded the millions of visitors to the TrialSite Community worldwide that WHO failed to mention what was in fact in those medicine kits: Ivermectin.  

During this entry, TrialSite asked the question of “why would the WHO omit that critically important fact? Why would they be so biased as to not report on the truth? What were they trying to hide?” The Hindustan Press reminded all at that time that Uttar Pradesh by May 28 accounted for about 74.55% of the new COVID-19 recoveries. TrialSite reported that the suppression and censorship of this information involved even local Indian media as they wouldn’t report on the fact that Ivermectin was involved in this dramatic turnaround that also involves an impressive public health initiative from door-to-door screenings and proactive provisioning of care.

Perhaps that’s why a lesser-known association of attorneys in India known as the Indian Bar Association actually served a legal notice to the head scientists of WHO.

Restrictions Lifted in 72 of 75 State Districts

According to the same database, the remarkable decline in Uttar Pradesh continues now with the most recent daily estimated count at 1,113 per day. When looked at in graph form, one views what can be deemed a complete and utter turnaround that must be better understood at least for other low-to middle-income countries (LMICs), although India is now the 5th richest economy in the world as measured by total GDP. If the present pace of decline continues within days, the count will be under 600.

And, in fact, the local press recently announced that this is the reality, as the state has lifted restrictions in all but a few of the 75 districts. The restrictions only apply to three zones as the number of active cases of COVID-19 fell below the 20,000 mark in total. Navneet Sehgal, an associate chief secretary, reported the curfew is maintained in three zones including Meerut, Saharanpur, and Gorakhpur as the active cases in those districts remain over 600.

Call to ActionTrialSite has a rapidly growing global community of people interested in research with a call for transparency, accessibility, and emphasis on advancement of biomedical research for all, whether it be community-based population health to the most advanced biopharmaceuticals. Sign up for the App for both iPhone or Android.

Responses